Virios up on FDA's positive feedback on lead drug candidate
24/04/2023 22:41
** Shares of Virios Therapeutics Inc VIRI.O rise 22% to
$0.76 in extended trade
** Co's proposal for late-stage study of IMC-1 is
acceptable, subject to review of certain toxicology reports -
FDA in initial feedback to co
** IMC-1 is co's lead drug candidate to suppress replication
of herpes virus and reduce fibromyalgia, a chronic disorder
causing pain, fatigue and sleeplessness; drug is on fast track
tag by FDA
** Co had proposed a development program for late-stage
study based on data from mid-stage study
** Final toxicology results to be submitted to FDA in May
2023 - VIRI
** Stock up 165% YTD
(Reporting by Aditya Samal)
((Aditya.Samal@thomsonreuters.com;))